Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is anticipated to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Castle Biosciences to post earnings of ($0.21) per share and revenue of $81.1890 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Castle Biosciences Stock Up 3.5%

CSTL stock opened at $29.94 on Wednesday. The company’s 50 day moving average price is $37.70 and its 200 day moving average price is $31.05. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. Castle Biosciences has a fifty-two week low of $14.59 and a fifty-two week high of $44.28. The firm has a market capitalization of $873.95 million, a price-to-earnings ratio of -66.53 and a beta of 1.06.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CSTL shares. KeyCorp reissued an “overweight” rating and issued a $50.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 29th. Lake Street Capital boosted their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Zacks Research raised Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, February 2nd. Guggenheim raised their price target on Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Canaccord Genuity Group lifted their price target on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.14.

Insider Activity

In other news, insider Derek J. Maetzold sold 817 shares of Castle Biosciences stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $37.99, for a total value of $31,037.83. Following the transaction, the insider directly owned 83,698 shares of the company’s stock, valued at $3,179,687.02. The trade was a 0.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Kristen M. Oelschlager sold 14,888 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total value of $585,247.28. Following the sale, the chief operating officer owned 12,323 shares of the company’s stock, valued at $484,417.13. This trade represents a 54.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 29,617 shares of company stock valued at $1,167,887 over the last three months. Company insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On Castle Biosciences

Several hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in shares of Castle Biosciences by 42.7% during the 4th quarter. Wells Fargo & Company MN now owns 34,212 shares of the company’s stock valued at $1,331,000 after acquiring an additional 10,233 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Castle Biosciences by 4.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 34,138 shares of the company’s stock valued at $1,328,000 after purchasing an additional 1,545 shares during the period. Counterpoint Mutual Funds LLC acquired a new position in Castle Biosciences during the fourth quarter worth approximately $504,000. Janus Henderson Group PLC raised its stake in Castle Biosciences by 64.6% during the fourth quarter. Janus Henderson Group PLC now owns 15,037 shares of the company’s stock worth $585,000 after purchasing an additional 5,900 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Castle Biosciences by 4.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,778 shares of the company’s stock valued at $633,000 after purchasing an additional 1,115 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.